| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.27 | 0.04 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.059 | 0.05 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |